Cell News and Research

RSS

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

7 Apr 2010

Actual cost of blood 37% higher than previously estimated

A new blood transfusion cost analysis study published in the April 2010 issue of Transfusion, a peer-reviewed academic journal, shows that when all of the complex cost factors leading up to and after a red blood cell (RBC) transfusion are considered, the actual cost of blood is substantially higher than previously estimated.

7 Apr 2010

Officials of Kylin Therapeutics receive an issued patent from USPTO

Officials of Kylin Therapeutics Inc., a leading RNAi company, announced this week that they received an issued patent from the U.S. Patent and Trademark Office.

7 Apr 2010

Researchers commence Phase 2 research study to test CERE-110 for AD

Researchers at Banner Sun Health Research Institute are about to start the first Phase 2 research study to test a gene transfer agent for Alzheimer's disease. AD is a degenerative and ultimately fatal disorder affecting as many as five million Americans and that number is expected to soar to more than 11 million by 2040.

7 Apr 2010

Study provides benchmark data to evaluate quality of management of sickle cell disease

The largest study to date of the use of acute care medical services by people with sickle cell disease found four of every 10 had to return to the hospital within 30 days of a previous hospitalization or go to the emergency department for treatment of pain, according to a new study funded in part by HHS' Agency for Healthcare Research and Quality.

7 Apr 2010

Research highlights first steps in the formation of Lewy bodies, the hallmark of Parkinson's brain

Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein. The research, published by Cell Press online on April 6th in Biophysical Journal, provides new insight into the first steps in the formation of neurotoxic structures called Lewy bodies that are the hallmark of the Parkinson's brain.

7 Apr 2010

Stimulant medication normalizes brain function in children with ADHD: Study

Attention-deficit/hyperactivity disorder is one of the most common mental health disorders affecting children and adolescents. Children with ADHD are excessively restless, impulsive, and distractible and experience difficulties at home and in school. Problems inhibiting behavior are a common theme for ADHD symptoms.

7 Apr 2010

TD2 to join GPEC at BayBio2010 to spur Arizona's bioscience industry

Scottsdale-based TGen Drug Development will join the Greater Phoenix Economic Council this week at BayBio2010 in an effort to spur Arizona's bioscience industry.

7 Apr 2010

Sickle cell disease: Rehospitalization rates high

7 Apr 2010

Jantibody Therapeutics, Pfenex collaborate in production of HSP-avidin fusion proteins

Boston BioCom LLC today announced the successful completion of a collaborative research agreement between its Jantibody Therapeutics LLC subsidiary and Pfenex Inc., resulting in the rapid production of a HSP-avidin fusion protein for the Jantibodies self-assembling vaccines platform.

7 Apr 2010

Defective protein responsible for SCA5 disease cuts synaptic terminals and snarls traffic inside neurons

The neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve cells in two ways. University of Minnesota researchers now report that the defective protein responsible for the disease cuts the number of synaptic terminals and snarls traffic inside neurons.

7 Apr 2010

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.

7 Apr 2010

Women with preeclampsia have fewer EPCs: Magee-Womens Research Institute

Compared to women with uncomplicated pregnancies, women with preeclampsia have reduced numbers of special cells that are thought to help grow and maintain blood vessels, according to a study by researchers at the Magee-Womens Research Institute and the University of Pittsburgh School of Medicine.

7 Apr 2010

SRU Biosystems extends product line with the introduction of BIND SCANNER

SRU Biosystems today announced the extension of its product line of label-free instrumentation and biosensors with the introduction of its BIND® SCANNER for primary and stem cell applications. The BIND SCANNER is a first-of-its-kind, plate-based, label-free instrument capable of monitoring cellular responses at an individual cell resolution.

7 Apr 2010

Anthera Pharmaceuticals announces closing of underwriters' exercise of over-allotment option

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the closing of the underwriters' exercise of their over-allotment option to purchase an additional 604,492 shares of Anthera's common stock, at a price of $7.00 per share.

7 Apr 2010

Stem cell-enriched autologous fat for breast augmentation

Whereas US and European medical centers are still beginners in breast augmentation with stem cell-enriched autologous fat, Viennese New Cosmetic Surgery and anti-aging expert DDr. Karl-Georg Heinrich is well-versed in this revolutionary method. In his Clinic DDr. Heinrich, he has been successfully offering breast augmentations with autologous stem cells to a broad public since early 2007.

7 Apr 2010

Patients with sickle cell disease require acute care: Study

Patients with sickle cell disease average about 2.5 hospital visits per year, with 18- to 30-year old patients more likely to require acute care or rehospitalization, according to a study in the April 7 issue of JAMA.

7 Apr 2010

MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL), in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. The trial, led by Shaji Kumar, MD, of Mayo Clinic, is open for enrollment at Mayo Clinic (Rochester, Minn.), City of Hope Cancer Center (Duarte, Calif.) and the University of Chicago (Chicago, Ill).

7 Apr 2010

Study: 75% of men with diabetes will develop some degree of ED

Erectile dysfunction is one of the most prevalent diabetes-induced complications in men; current estimates suggest that as many as 75% of men with diabetes will develop some degree of ED, and in many cases diabetics develop more severe forms of ED that are less responsive to standard drugs.

7 Apr 2010

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Genta Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's request for "Fast Track" designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

7 Apr 2010

Cell News and Research

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Actual cost of blood 37% higher than previously estimated

Officials of Kylin Therapeutics receive an issued patent from USPTO

Researchers commence Phase 2 research study to test CERE-110 for AD

Study provides benchmark data to evaluate quality of management of sickle cell disease

Research highlights first steps in the formation of Lewy bodies, the hallmark of Parkinson's brain

Stimulant medication normalizes brain function in children with ADHD: Study

TD2 to join GPEC at BayBio2010 to spur Arizona's bioscience industry

Sickle cell disease: Rehospitalization rates high

Jantibody Therapeutics, Pfenex collaborate in production of HSP-avidin fusion proteins

Defective protein responsible for SCA5 disease cuts synaptic terminals and snarls traffic inside neurons

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Women with preeclampsia have fewer EPCs: Magee-Womens Research Institute

SRU Biosystems extends product line with the introduction of BIND SCANNER

Anthera Pharmaceuticals announces closing of underwriters' exercise of over-allotment option

Stem cell-enriched autologous fat for breast augmentation

Patients with sickle cell disease require acute care: Study

MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone

Study: 75% of men with diabetes will develop some degree of ED

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo